沃森生物(300142.SZ)子公司收到13价肺炎结合疫苗埃及上市许可证

Core Viewpoint - Watson Bio's subsidiary, Yuxi Watson Biotechnology Co., Ltd., has received a marketing authorization for its 13-valent pneumococcal polysaccharide conjugate vaccine from the Egyptian Drug Authority, marking a significant milestone for the company's product expansion in international markets [1] Group 1 - The 13-valent pneumococcal conjugate vaccine has been granted a marketing license in Egypt [1] - This approval indicates the company's successful entry into the Egyptian pharmaceutical market [1] - The vaccine is expected to enhance the company's product portfolio and revenue potential [1]